Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema

被引:8
|
作者
Abdel-Hay, Ahmed [1 ,2 ]
Sivaprasad, Sobha [3 ]
Subramanian, Ahalya [1 ]
Barbur, John L. [1 ]
机构
[1] City Univ London, Appl Vis Res Ctr, London, England
[2] Musgrove Pk Hosp, Taunton, Somerset, England
[3] Moorfields Eye Hosp, London, England
来源
PLOS ONE | 2018年 / 13卷 / 06期
关键词
CHROMATIC SENSITIVITY; NEURAL APOPTOSIS; CLASSIFICATION; TRIAMCINOLONE; RETINOPATHY; PREVALENCE; PATHWAYS; HYPOXIA; SYSTEM;
D O I
10.1371/journal.pone.0199693
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose To evaluate changes in colour vision following intravitreal injection of Dexamethasone implant (Ozurdex) in patients with diabetic macular oedema (DMO). Both red-green (RG) and yellow-blue (YB) chromatic sensitivity were assessed using the Colour Assessment & Diagnosis (CAD) test which isolates the use of colour signals and provides age-corrected, statistical limits for normal trichromats. To determine whether colour changes and visual acuity (VA) post-treatment relate to central sub-field retinal thickness (CST). Methods Fourteen patients with DMO who were undergoing treatment with Ozurdex were recruited for this study. RG and YB colour thresholds were measured using the CAD test, best corrected visual acuity was assessed using the ETDRS chart and CST was measured using spectral domain optical coherence tomography (SD-OCT). All tests were performed monocularly at baseline and 24 weeks post injection. Results All patients (n = 14 eyes), had significant loss of RG and YB chromatic sensitivity at baseline (p<0.05). The mean age was 56 +/- 9.5 years. The age specific, monocular, upper normal limits for a 56 year old subject are 2.66 for RG and 2.85 for YB. In this study, the measured, pre injection thresholds (mean +/- SD) were 22.6 +/- 11.3 for RG and 16.2 +/- 3.76 for YB. There was significant improvement in RG threshold post injection (i.e., 19.2 +/- 10.8 (p<0.05)). No significant changes were found in the YB thresholds with corresponding mean and range values of: 15.8 +/- 4.6 (p = 0.23). CST pre-treatment was 542 +/- 135 mu m. After treatment and by week 24 the CST values decreased to 435 +/- 127 mu m. Conclusions RG colour thresholds provide a sensitive measure of functional change in diabetic subjects with macular oedema. The YB system is damaged severely in the DMO patients studied and shows little or no recovery post treatment. The improvement in VA and particularly in RG colour vision correlate well with the measured decrease in CST. The results suggest that the improvement in the RG chromatic sensitivity can provide a useful biomarker for monitoring the efficacy of treatment in DMO.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Macular hole after injection of dexamethasone intravitreal implant for macular oedema due to central retinal vein occlusion
    De Benedetto, Umberto
    Parodi, Maurizio Battaglia
    Knutsson, Karl Anders
    Lattanzio, Rosangela
    Bandello, Francesco
    Iacono, Pierluigi
    ACTA OPHTHALMOLOGICA, 2013, 91 (01) : e75 - e77
  • [22] RESULTS OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX®) IN CASES WITH RESISTANT DIABETIC MACULAR OEDEMA AND HARD EXUDATES IN THE MACULAR CENTER
    Dikci, S.
    Yilmaz, T.
    Yesiloz, O.
    Ozturk, E.
    Genc, O.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2016, 26 (04) : E109 - E109
  • [23] Dexamethasone implant in diabetic macular edema patients with high visual acuity
    Sacconi, Riccardo
    Parodi, Maurizio Battaglia
    Casati, Stefano
    Lattanzio, Rosangela
    Bandello, Francesco
    Marchini, Giorgio
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [24] INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMA
    Zhioua, Imene
    Semoun, Oudy
    Lalloum, Franck
    Souied, Eric H.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (07): : 1429 - 1435
  • [25] Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema
    Guigou, Sebastien
    Pommier, Stephan
    Meyer, Franck
    Hajjar, Christian
    Merite, Pierre Yves
    Parrat, Eric
    Rouhette, Herve
    Rebollo, Olivier
    Matonti, Frederic
    OPHTHALMOLOGICA, 2015, 233 (3-4) : 169 - 175
  • [26] OCT-Angiography Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Dexamethasone Implant
    Carnota-Mendez, Pablo
    Mendez-Vazquez, Carlos
    Perez-Gavela, Conchi
    CLINICAL OPHTHALMOLOGY, 2022, 16 : 247 - 263
  • [27] Dexamethasone intravitreal implant in patients with cataract and naive diabetic macular edema
    Barone, Antonio
    Russo, Vincenzo
    Maggiore, Giulia
    Loiodice, Marco Sabino
    Stella, Andrea
    Bux, Anna Valeria
    Iaculli, Cristiana
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (01) : 364 - 371
  • [28] Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema
    Dutra Medeiros, Marco
    Postorino, Maurizio
    Navarro, Rafael
    Garcia-Arumi, Jose
    Mateo, Carlos
    Corcostegui, Borja
    OPHTHALMOLOGICA, 2014, 231 (03) : 141 - 146
  • [29] DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS
    Boyer, David S.
    Faber, David
    Gupta, Sunil
    Patel, Sunil S.
    Tabandeh, Homayoun
    Li, Xiao-Yan
    Liu, Charlie C.
    Lou, Jean
    Whitcup, Scott M.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (05): : 915 - 923
  • [30] Treatment algorithm with dexamethasone intravitreal implant in patients with diabetic macular edema
    Epstein, David
    Mirabelli, Pierfrancesco
    Lovestam Adrian, Monica
    ACTA OPHTHALMOLOGICA, 2020, 98 (04) : E528 - E529